We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Study enrolled 268 patients, exceeding target enrollment. Largest interventional study ever to be conducted in pulmonary sarcoidosis. Topline data are expected in the third quarter of 2025. SAN...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.12 | 6.89655172414 | 1.74 | 1.81 | 1.58 | 323980 | 1.70881284 | CS |
4 | 0.32 | 20.7792207792 | 1.54 | 1.81 | 1.46 | 282346 | 1.61455067 | CS |
12 | 0.11 | 6.28571428571 | 1.75 | 2.07 | 1.42 | 353294 | 1.68208604 | CS |
26 | 0.11 | 6.28571428571 | 1.75 | 2.07 | 1.42 | 353294 | 1.68208604 | CS |
52 | 0.11 | 6.28571428571 | 1.75 | 2.07 | 1.42 | 353294 | 1.68208604 | CS |
156 | 0.11 | 6.28571428571 | 1.75 | 2.07 | 1.42 | 353294 | 1.68208604 | CS |
260 | 0.11 | 6.28571428571 | 1.75 | 2.07 | 1.42 | 353294 | 1.68208604 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions